ATRS News and Press, Antares Pharma Inc. From 05/06/21

Antares Pharma (ATRS) posted first-quarter results that beat Wall Street estimates, as the company benefited from an increase in prescriptions and patient visits due to the slowdown of the COVID-19 pandemic.The company also reaffirmed FY 2021 revenue guidance in the range of $175M-200M, which...

EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pur...

Increased Revenue 27% Year-Over-Year to $42.1 Million Increased Net Income to $3.8 Million, or $0.02 Per Basic and Diluted Earnings Per Share EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharma...

EWING, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that data highlighting the therapeutic potential of subcutaneous testosterone enanthate in younger hypogonadal populations was...

EWING, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to participate and host investor meetings at the 7...

EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the market opens. ...

Antares Pharma operates in crowded markets with relatively low barriers to entry and intense competition. Their flagship product, XYOSTED, grew significantly in 2019 and 2020 but competitors may enter the market as soon as October 2021. Their business model forces them to be secre...

Antares Pharma (ATRS) has appointment Peter Richardson, MRCP, as Executive VP, R&D and Chief Medical Officer.In this role, Dr. Richardson will oversee the Company’s proprietary research and development programs, including ideation, formulation, clinical operations, pharmacovig...

EWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as Executive Vice President, Research and Development and Chief Medical Officer. ...

The following slide deck was published by Antares Pharma, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Antares Pharma, Inc. 2020 Q4 - Results - Earnings Call Presentation